US FDA advisers vote against Otsuka's PTSD combination treatment
18/07/2025 20:45
July 18 (Reuters) - The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's 4578.T drug when used in combination with Viatris' VTRS.O Zoloft for the treatment of adults with PTSD. (Reporting by Siddhi Mahatole and Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar) ((siddhi.mahatole@thomsonreuters.com))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug